Andrej Besse
Medizinische Onkologie und Hämatologie · Dept. I
Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
Mendez Lopez M, Besse A, Besse L, Kraus M, Driessen C (2023). Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma.
Nov 28, 2023Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
Nov 28, 2023ASH 2023
Mendez Lopez Max, Besse Andrej, Besse Lenka, Kraus Marianne, Driessen Christoph
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt M, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Mendez Lopez M, Munawar U, Riedel A, Han S, Maurits E, Overkleeft H, Florea B, Einsele H, Kortüm K, Driessen C, Besse L, Rasche L. High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Haematologica 2023; 108:1628-1639.
Jun 1, 2023High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Jun 1, 2023Haematologica 2023; 108:1628-1639
Zhou Xiang, Besse Andrej, Peter Jessica, Steinhardt Maximilian Johannes, Vogt Cornelia, Nerreter Silvia, Teufel Eva, Stanojkovska Emilia, Xiao Xianghui, Hornburger Hannah, Haertle Larissa, Mendez Lopez Max, Munawar Umair, Riedel Angela, Han Seungbin, Maurits Elmer, Overkleeft Hermann S, Florea Bogdan I, Einsele Hermann, Kortüm K Martin, Driessen Christoph, Besse Lenka, Rasche Leo
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.
Mar 17, 2023The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Mar 17, 2023Sci Rep 2023; 13:4411
Besse Lenka, Kraus Marianne, Besse Andrej, Driessen Christoph, Tarantino Ignazio
Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.
Oct 3, 2022Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Oct 3, 2022Clin Case Rep 2022; 10:e6296
Kliebhan Johannes, Besse Andrej, Kampa-Schittenhelm Kerstin M, Schittenhelm Marcus, Driessen Christoph
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.
May 26, 2022Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
May 26, 2022Front Oncol 2022; 12:899272
Schwestermann Jonas, Besse Andrej, Driessen Christoph, Besse Lenka
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Yurchenko A, Pop O, Ighilahriz M, Padioleau I, Rajabi F, Sharpe H, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage F, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev S. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. Clin Cancer Res 2022; 28:1422-1432.
Apr 1, 2022Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.
Apr 1, 2022Clin Cancer Res 2022; 28:1422-1432
Yurchenko Andrey A, Pop Oltin, Ighilahriz Meriem, Padioleau Ismael, Rajabi Fatemeh, Sharpe Hayley J, Poulalhon Nicolas, Dreno Brigitte, Khammari Amir, Delord Marc, Alberti Antonio, Soufir Nadem, Battistella Maxime, Mourah Samia, Bouquet Fanny, Savina Ariel, Besse Andrej, Mendez Lopez Max, Grange Florent, Monestier Sandrine, Mortier Laurent, Meyer Nicolas, Dutriaux Caroline, Robert Caroline, Saiag Philippe, Herms Florian, Lambert Jerome, de Sauvage Frederic J, Dumaz Nicolas, Flatz Lukas, Basset-Seguin Nicole, Nikolaev Sergey
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Besse A, Kraus M, Mendez Lopez M, Maurits E, Overkleeft H, Driessen C, Besse L. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors. Cells 2022; 11
Mar 1, 2022Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Mar 1, 2022Cells 2022; 11
Besse Andrej, Kraus Marianne, Mendez Lopez Max, Maurits Elmer, Overkleeft Hermann S, Driessen Christoph, Besse Lenka
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Bolomsky A, Caers J, Hübl W, Schreder M, Zojer N, Driessen C, Tang J, Besse L, Heckman C, Kubicek S, Hannich J, Miettinen J, Malyutina A, Besse A, Huber J, Fellinger S, Breid H, Parsons A, Klavins K, Ludwig H. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5:4125-4139.
Oct 26, 2021Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Oct 26, 2021Blood Adv 2021; 5:4125-4139
Bolomsky Arnold, Caers Jo, Hübl Wolfgang, Schreder Martin, Zojer Niklas, Driessen Christoph, Tang Jing, Besse Lenka, Heckman Caroline A, Kubicek Stefan, Hannich J Thomas, Miettinen Juho J, Malyutina Alina, Besse Andrej, Huber Julia, Fellinger Stefanie, Breid Helene, Parsons Alun, Klavins Kristaps, Ludwig Heinz
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells 2021; 10
Oct 22, 2021High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Oct 22, 2021Cells 2021; 10
Besse Lenka, Besse Andrej, Kraus Marianne, Maurits Elmer, Overkleeft Herman S, Bornhauser Beat, Bourquin Jean-Pierre, Driessen Christoph
Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion
Mendez Lopez M, Besse A, Florea B, Zuppinger C, Overkleeft H, Besse L, Driessen C (2021). Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion.
Sep 8, 2021Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion
Sep 8, 202118th International Myeloma Workshop
Mendez Lopez Max, Besse Andrej, Florea Bogdan, Zuppinger Christian, Overkleeft Herman S, Besse Lenka, Driessen Christoph
Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment
Ring S, Spiegl M, Besse A, Bonilla W, Stemeseder F, Schmidt S, Orlinger K, Krebs P, Ludewig B, Wenger R, Hartmann F, Cupovic J, Onder L, Lütge M, Perez Shibayama C, Gil Cruz C, Scandella E, De Martin A, Mörbe U, Flatz L. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nat Commun 2021; 12:4734.
Aug 5, 2021Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment
Aug 5, 2021Nat Commun 2021; 12:4734
Ring Sandra, Spiegl Matthias, Besse Andrej, Bonilla Weldy V, Stemeseder Felix, Schmidt Sarah, Orlinger Klaus K, Krebs Philippe, Ludewig Burkhard, Wenger Robert, Hartmann Fabienne, Cupovic Jovana, Onder Lucas, Lütge Mechthild, Perez Shibayama Christian, Gil Cruz Cristina, Scandella Elke, De Martin Angelina, Mörbe Urs, Flatz Lukas
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Besse L, Bolomsky A, Ludwig H, Hannich J, Loguinov A, Everts B, Berkers C, Pilon M, Farhan H, Vulpe C, Overkleeft H, Huber J, Ståhlman M, Borén J, Besse A, Stolze S, Sobh A, Zaal E, van der Ham A, Ruiz M, Phuyal S, Büchler L, Sathianathan M, Florea B, Driessen C. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Res 2021; 81:4581-4593.
Jun 22, 2021Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Jun 22, 2021Cancer Res 2021; 81:4581-4593
Besse Lenka, Bolomsky Arnold, Ludwig Heinz, Hannich J Thomas, Loguinov Alex, Everts Bart, Berkers Celia R, Pilon Marc, Farhan Hesso, Vulpe Christopher D, Overkleeft Herman S, Huber Julia, Ståhlman Marcus, Borén Jan, Besse Andrej, Stolze Sara C, Sobh Amin, Zaal Esther A, van der Ham Alwin J, Ruiz Mario, Phuyal Santosh, Büchler Lorina, Sathianathan Marc, Florea Bogdan I, Driessen Christoph
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. Hemasphere 2021; 5:e602.
Jun 12, 2021Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Jun 12, 2021Hemasphere 2021; 5:e602
Byrgazov Konstantin, Besse Andrej, Kraus Marianne, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2020; 101:106499.
Dec 31, 2020Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Dec 31, 2020Leuk Res 2020; 101:106499
Byrgazov Konstantin, Kraus Marianne, Besse Andrej, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Besse L, Besse A, Mendez Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira R, Castellano R, Law B, Driessen C. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica 2019; 104:e415-e419.
Feb 21, 2019A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Feb 21, 2019Haematologica 2019; 104:e415-e419
Besse Lenka, Besse Andrej, Mendez Lopez Max, Vasickova Katerina, Sedlackova Miroslava, Vanhara Petr, Kraus Marianne, Bader Jürgen, Ferreira Renan B, Castellano Ronald K, Law Brian K, Driessen Christoph
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A, Besse L, Kraus M, Mendez Lopez M, Bader J, Xin B, de Bruin G, Maurits E, Overkleeft H, Driessen C. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chem Biol 2019; 26:340-351.e3.
Jan 3, 2019Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Jan 3, 2019Cell Chem Biol 2019; 26:340-351.e3
Besse Andrej, Besse Lenka, Kraus Marianne, Mendez Lopez Max, Bader Jürgen, Xin Bo-Tao, de Bruin Gerjan, Maurits Elmer, Overkleeft Hermann S, Driessen Christoph
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Barrio S, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou R, Braggio E, Stewart A, Raab M, Einsele H, Driessen C, Chatterjee M, Leich E, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Kortüm K. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2018
Jul 19, 2018Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Jul 19, 2018Leukemia 2018
Barrio Santiago, Martinez-Lopez Joaquin, Rosenwald Andreas, Beckmann Roland, Bargou Ralf C, Braggio Esteban, Stewart A Keith, Raab Marc S, Einsele Hermann, Driessen Christoph, Chatterjee Manik, Leich Ellen, Stühmer Thorsten, Da-Viá Matteo, Barrio-Garcia Clara, Lehners Nicola, Besse Andrej, Cuenca Isabel, Garitano-Trojaola Andoni, Fink Severin, Kortüm K Martin
The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.
Mar 15, 2018The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Mar 15, 2018JOR Spine 2018; 1:e1003
Krupkova Olga, Cambria Elena, Besse Lenka, Besse Andrej, Bowles Robert, Wuertz-Kozak Karin
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
Nov 21, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Nov 21, 2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka